Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients
J Havlin, M Svorcova, E Dvorackova… - The Journal of Heart and …, 2021 - Elsevier
The immunogenicity of the novel mRNA COVID-19 vaccine in immunocompromised lung
transplant recipients is still unknown. We compared the antibody response after the first and
second doses of the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) with the
response after natural SARS-CoV-2 infection in lung transplant recipients. None of the
vaccinees tested after two doses of the mRNA BNT162b2 vaccine developed anti-SARS-
CoV-2 IgG, while 85% patients presented an antibody response after SARS-CoV-2 infection …
transplant recipients is still unknown. We compared the antibody response after the first and
second doses of the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) with the
response after natural SARS-CoV-2 infection in lung transplant recipients. None of the
vaccinees tested after two doses of the mRNA BNT162b2 vaccine developed anti-SARS-
CoV-2 IgG, while 85% patients presented an antibody response after SARS-CoV-2 infection …
